trending Market Intelligence /marketintelligence/en/news-insights/trending/qNszSzT6y7VcflslsJbeMw2 content esgSubNav
In This List

60° Pharmaceuticals seeks US FDA approval for preventive malaria medication

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


60° Pharmaceuticals seeks US FDA approval for preventive malaria medication

60° Pharmaceuticals LLC is seeking approval from the U.S. Food and Drug Administration for Tafenoquine for the prevention of malaria in adults.

The company entered into a cooperative research and development agreement with the U.S. Army Medical Materiel Development Activity in 2014 for the development of the drug.

Tafenoquine has been studied in more than 30 clinical trials involving more than 4,000 participants.